Recent Finacing
Recent Raise
ImmusanT is a clinical-stage biotech developing epitope-specific immunotherapies, including peptide vaccine Nexvax2 for HLA-DQ2.5 celiac patients, alongside companion and blood-based T-cell diagnostics.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at ImmusanT.
